Skip to search formSkip to main contentSkip to account menu
You are currently offline. Some features of the site may not work correctly.

monoclonal antibody CNTO 328

Known as: CNTO-328, monoclonal antibody CNTO-328, CNTO 328 monoclonal antibody 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

siltuximab

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2013
2013
A novel approach for the simultaneous quantification of a therapeutic monoclonal antibody in serum produced from two distinct host cell lines
Therapeutic monoclonal antibodies (mAbs) possess a high degree of heterogeneity associated with the cell expression system… 
Review
2012
Review
2012
Novel Therapies for Metastatic Renal Cell Carcinoma: Efforts to Expand beyond the VEGF/mTOR Signaling Paradigm
With six agents approved for metastatic renal cell carcinoma (mRCC) within the past 5 years, there has undoubtedly been progress… 
  • figure 1
  • table 1
  • figure 2
Highly Cited
2009
Highly Cited
2009
Targeted inhibition of interleukin‐6 with CNTO 328 sensitizes pre‐clinical models of multiple myeloma to dexamethasone‐mediated cell death
Interleukin (IL)‐6‐mediated signalling attenuates the anti‐myeloma activity of glucocorticoids (GCs). We therefore sought to… 
Review
2009
Review
2009
Targeting IL-6 in the treatment of inflammatory and autoimmune diseases
Background: IL-6, a glycoprotein composed of 212 amino acids in human, has a wide range of biological activity, including… 
2008
2008
A Phase I Study of CNTO 328, An Anti-Interleukin-6 Monoclonal Antibody in Patients with B-Cell Non-Hodgkin’s Lymphoma, Multiple Myeloma, or Castleman’s Disease.
Interleukin (IL)-6 is a multifunctional cytokine that serves as a growth factor for B-cell non-Hodgkin’s lymphoma (NHL), multiple… 
2006
2006
Regulation of growth of prostate cancer cells selected in the presence of interleukin‐6 by the anti‐interleukin‐6 antibody CNTO 328
Interleukin‐6 (IL‐6) is a multifunctional regulator of cellular events in prostate cancer. LNCaP‐IL‐6+ cells selected in the… 
2006
2006
Gateways to clinical trials.
Gateways to Clinical Trials are a guide to the most recent clinical trials in current literature and congresses. The data the… 
2006
2006
Phase I, multicenter trial of CNTO 328, an anti-interleukin(IL)-6 monoclonal antibody (mAb) in subjects with selected hematologic malignancies.
2513 Background: IL-6 is implicated in the pathophysiology of several malignant diseases, including multiple myeloma (MM) and… 
Review
2005
Review
2005
CNTO-328 (Centocor).
Highly Cited
2004
Highly Cited
2004
CNTO 328, a monoclonal antibody to IL‐6, inhibits human tumor‐induced cachexia in nude mice
IL‐6 is a multifunctional cytokine implicated in several cancers. IL‐6 is a growth factor for certain tumors and contributes to… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE